Jane E Rogers
Overview
Explore the profile of Jane E Rogers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rogers J, Leung M, Ajani J
Expert Opin Drug Metab Toxicol
. 2025 Feb;
:1-6.
PMID: 40015974
Introduction: Gastric adenocarcinoma (GAC) represents a heterogeneous disease making treatment advancements difficult. Recently, claudin 18.2 (CLDN18.2) has emerged as an exciting new target in GAC. Zolbetuximab, an anti-CLDN18.2 monoclonal antibody,...
2.
Rogers J, Ajani J
Expert Rev Anticancer Ther
. 2025 Feb;
:1-7.
PMID: 39918299
Introduction: Gastric and gastroesophageal adenocarcinomas (GEACs) continue to carry a poor prognosis in most patients. New and exciting therapies have entered the treatment landscape in recent years. Prior to these...
3.
Rogers J, Leung M, Ajani J
Expert Rev Clin Pharmacol
. 2024 Dec;
18(1-2):1-3.
PMID: 39737726
No abstract available.
4.
Rogers J, Ajani J
Expert Rev Clin Pharmacol
. 2024 Dec;
17(12):1093-1094.
PMID: 39652390
No abstract available.
5.
Rogers J, Gan Q, Waters R, Horak A, Ajani J
Expert Opin Biol Ther
. 2024 Sep;
24(10):1005-1015.
PMID: 39315517
Introduction: Gastric adenocarcinoma (GAC) remains a prevalent cancer worldwide and its incidence is increasing in South America. The heterogenous nature of GAC makes advances in management challenging. Areas Covered: Despite...
6.
Sewastjanow-Silva M, Kwiatkowski E, Yamashita K, Abdelhakeem A, Yoshimura K, Vicentini E, et al.
Int J Cancer
. 2024 Jul;
155(12):2277-2286.
PMID: 38995150
Human epidermal growth factor receptor-2 (HER2), programmed death-ligand 1 (PD-L1), and microsatellite (MS) status are well-established biomarkers in gastroesophageal adenocarcinomas (GEAs). However, it is unclear how the combination of these...
7.
Rogers J, Ajani J
Curr Opin Oncol
. 2024 May;
36(4):308-312.
PMID: 38726797
Purpose Of Review: Claudins, components of tight cell junctions in epithelial and endothelial cells, have emerged as a therapeutic target in gastrointestinal (GI) malignancies, particularly claudin 18.2 (CLDN18.2). Recent Findings:...
8.
Sewastjanow-Silva M, Xiao L, Gonzalez G, Wang X, Hofstetter W, Swisher S, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611056
Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve...
9.
Yamashita K, Sewastjanow-Silva M, Yoshimura K, Rogers J, Vicentini E, Pizzi M, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38610978
Background: The clinical impact of SMARCA4 mutations (SMARCA4ms) in gastroesophageal adenocarcinoma (GEA) remains underexplored. This study aimed to examine the association of SMARCA4ms with clinical outcomes and co-occurrence with other...
10.
Rogers J, Zadlo J, Leung C, Nguyen V, Leung M, Mace M, et al.
JCO Oncol Pract
. 2024 Feb;
20(6):808-815.
PMID: 38412400
Purpose: GI medical oncology care presents unique medication challenges. Here, we captured our clinical pharmacy specialists' (CPSs) involvement in patients with GI cancers starting cycle 1 of a new treatment....